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Abstract
Background: The prevalence of depression in people receiving haemodialysis is high with estimates varying
between 20 and 40 %. There is little research on the effectiveness of antidepressants in dialysis patients with the
few clinical trials suffering significant methodological issues. We plan to carry out a study to evaluate the feasibility
of conducting a randomised controlled trial in patients on haemodialysis who have diagnosed Major Depressive
Disorder.
Methods/Design: The study has two phases, a screening phase and the randomised controlled trial. Patients will
be screened initially with the Beck Depression Inventory to estimate the number of patients who score 16 or
above. These patients will be invited to an interview with a psychiatrist who will invite those with a diagnosis of
Major Depressive Disorder to take part in the trial. Consenting patients will be randomised to either Sertraline or
placebo. Patients will be followed-up for 6 months.
Demographic and clinical data will be collected at screening interview, baseline interview and 2 weeks, and every
month (up to 6 months) after baseline. The primary outcome is to evaluate the feasibility of conducting a randomised,
double blind, placebo pilot trial in haemodialysis patients with depression. Secondary outcomes include estimation of
the variability in the outcome measures for the treatment and placebo arms, which will allow for a future adequately
powered definitive trial. Analysis will primarily be descriptive, including the number of patients eligible for the trial,
drug exposure of Sertraline in haemodialysis patients and the patient experience of participating in this trial.
Discussion: There is an urgent need for this research in the dialysis population because of the dearth of good quality
and adequately powered studies. Research with renal patients is particularly difficult as they often have complex
medical needs. This research will therefore not only assess the outcome of anti-depressants in haemodialysis patients
with depression but also the process of running a randomised controlled trial in this population. Hence, the outputs of
this feasibility study will be used to inform the design and methodology of a definitive study, adequately powered to
determine the efficacy of anti-depressants in patient on haemodialysis with depression.
Trial registration: ISRCTN registry ISRCTN06146268 and EudraCT reference: 2012-000547-27.
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Background
The prevalence of people receiving renal replacement
therapy (RRT) for end stage renal disease (ESRD) is in-
creasing worldwide. In the UK around 900 people per
million were receiving these therapies in 2013, with ap-
proximately equal numbers on dialysis and transplant-
ation [1]. These numbers continue to increase by about
4 % annually. People on dialysis have a high symptom
burden and a greatly increased mortality [2, 3]. Depression
is common but difficult to diagnose because of the symp-
tom overlap between depression and advanced kidney
disease [4]. Estimates of prevalence of depression in this
population vary from around 40 %, based on self-reported
questionnaire screening, to around 20 %, on psychiatric
interview [4, 5]. Depression in dialysis patients is associated
with reduced quality of life, increased prevalence of cardio-
vascular disease, and increased mortality [6, 7]. Depression
may also lead to reduced treatment adherence, reduced
self-care behaviour, and subsequently greater healthcare
resource utilisation [8, 9]. Therefore attempts to identify
feasible and effective treatments for depression in this set-
ting remain a clinical priority.
There has been little research on the effectiveness of
antidepressant medication in dialysis patients. A 2009
Cochrane review identified only one Randomised Con-
trolled Trial (RCT), a small trial with 14 patients, which
had inconclusive results [10, 11]. While the trends indi-
cated that Fluoxetine was more effective than placebo, the
study was under powered. Other studies undertaken to
date have similarly been of limited size and design and
have lacked appropriate control groups [12–16]. It is
perhaps unsurprising that a recent systematic review,
including recommendations by the European Renal Best
Practice Group, recommended a well-designed RCT in
this setting [17].
In keeping with this recommendation, our primary
outcome is to undertake a study to evaluate the feasibility
of conducting a randomised, double blind, placebo con-
trolled trial in patients with ESRD on haemodialysis (HD)
who have a diagnosis of Major Depressive Disorder (MDD)
according to DSM-IV. Our study will explore key methodo-
logical, design, safety and drug exposure and acceptability
issues, including the number of ESRD patients who are eli-
gible to take part in the trial, in order to facilitate the design
of a subsequent large scale study. Our secondary aims are
to estimate the variability in the outcome measures for
the treatment and placebo arms, allowing an assessment
of effect sizes, effects of treatment centre, and bias due to
missing data in order to power a future definitive trial in
this setting. The antidepressant under investigation will be
Sertraline, a licensed selective serotonin reuptake inhibitor
(SSRI). Of the SSRIs available a recent meta-analysis
recommended Sertraline due to its favourable balance
between efficacy and acceptability, and low cost [18].
Sertraline also has a robust safety profile for cardiac
disease [19], the prevalence of which is high in ESRD.
It is also highly protein bound and almost entirely
hepatically cleared [20]. No dose adjustment is believed
to be required in ESRD though there is some evidence
that Sertraline’s elimination half-life is extended in ESRD
[21]. Thus our study will also determine pre- and post-
dialysis drug levels in these haemodialysed patients.
Methods/Design
Funding and governance
The study is funded by the National Institute for Health
Research programme, Research for Patient Benefit. The
reference number is PB-PG-0110-21073. The study re-
ceived ethical approval from NRES London-Harrow (REC
reference 12/LO/1554; IRAS project ID 100774). The trial
is co-sponsored by East and North Herts Trust NHS Trust
and the University of Hertfordshire. The Clinical Trials
Unit involved is Norwich Clinical Trials Unit, University
of East Anglia. The conduct of the trial will be overseen by
a Steering group which will meet at least 6 monthly and
will include the Chief Investigator (CI), all Principal Inves-
tigators (PIs), the Trial manager and lay members. A Data
Monitoring and Ethics Committee, consisting of inde-
pendent statistician, clinician, and lay person, will meet at
least twice during the course of the study.
Setting
The study will take place in four UK Renal Centres, the
Lister Hospital in Stevenage, Hertfordshire, Southend
Hospital in Essex, the Royal Free Hospital in London,
and the Queen Elizabeth Hospital in Birmingham. By
the end of 2012, the number of adults receiving HD at
each centre was as follows: Lister Hospital 409 patients,
Southend 118 patients, Royal Free Hospital 714 patients
and Queen Elizabeth Hospital 926 patients [22].
Overview of design
The study is planned in two phases – a screening phase
and a trial phase.
Screening phase
Initially patients on HD will be screened for eligibility
using the Beck Depression Inventory, version II (BDI-II)
[23] and other questionnaires. Patients who have been
identified on screening to have a high likelihood of suf-
fering from MDD, and who meet the eligibility criteria
will be invited to see the study psychiatrist to carry out a
diagnostic interview [24, 25]. Those diagnosed with
MDD will be invited to participate in the randomised
controlled trial.
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Trial phase
Consenting patients with be randomised to receive ei-
ther sertraline, initial dose 50 mg daily, or placebo for a
planned duration of 6 months with follow up at 2 weeks
and then monthly (Fig. 1)
Participants
Inclusion/Exclusion criteria
Screening Patients with ESRD, aged 18 or over, who have
been on HD for at least 3 months, and who speak and
read English well enough to complete the questionnaires.
Psychiatric interview Patients with a BDI-II [23] of 16 or
more on screening with a likely prognosis of more than one
year. Exclusion criteria include: treatment for anxiety or de-
pression during the previous 3 months with either antide-
pressants or formal psychological therapy; planned living
donor transplant within the period of the trial; pregnancy
or childbearing potential without adequate birth control;
contraindicated coexistent drug therapy (sertraline SmPC),
including triptans, antipsychotics, dopamine antagonists,
tramadol, linezolid, warfarin; hepatic impairment - alanine
transaminase more than twice the upper limit of normal
and/or INR greater than 1.3; Hepatitis, HIV/AIDS, and
Creutzfeldt-Jakob disease.
Trial phase Patients with a diagnosis of mild to moderate
MDD according to a DSM-IV interview, who score 18 or
above on the MADRS [25], and who have the capacity to
understand the trial and to give consent. Exclusions will in-
clude: a diagnosis of a severe MDD and those judged to be
at moderate to severe risk of self-harm who will be referred
immediately for further psychiatric evaluation; other psychi-
atric conditions including substance dependency, psychosis,
personality disorder, dementia or panic disorder, with the
exception of other anxiety disorders.
Sample size
A sample size of 60 in the Trial Phase will provide estimates
of the population variance to a precision of 1.2 x the sample
variance allowing reliable estimates to be derived for the
outcome measures, and inform design of the planned full
scale trial. This will require 800 patients to be screened.
The assumptions on which this estimate is based are: 30 %
of patients will screen positive on the BDI-II [22] and that
approximately 50 % of those patients will be subsequently
be diagnosed with MDD following a psychiatric interview
and that 50 % will agree to take part on the Trial Outcomes
phase – e.g. 7.5 % of the sampled patients.
Consent
Subjects will be required to give informed consent up to
four occasions, the screening phase, for psychiatric inter-
view, for the trial phase, and for a qualitative interview
conducted towards the end of the trial phase.
Randomisation
Following the diagnostic interview, eligible, consenting
patients with diagnosed MDD will be randomised by the
research psychiatrist. Both the research psychiatrist and
patient will be blind to the allocation. Randomisation
will take place in blocks using pre-prepared codes for
each centre. These will be incorporated into a protected
web based randomisation programme prepared by Norwich
CTU. Only the research psychiatrist will have authorised
access to the online randomisation programme. Following
randomisation the relevant pharmacy will be informed of
the allocation (treatment A or B) by automatically gener-
ated email. The pharmacist will be blind to the allocation.
The CTU will hold the patient-specific allocation data on a
secure server. The CI and PI at each centre will have access
to this data file only via a special log-in should the need
arise to unblind. No user identifiable data will stored in the
randomisation database. Web traffic will be encrypted using
standard secure sockets layer technology.
Fig. 1 Schematic diagram of overall design
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Intervention and control group
Intervention group
The drug under investigation is Sertraline hydrochloride
which will be provided in over-encapsulated form identical
to the placebo.
Control group
The study placebo is microcrystalline cellulose and magne-
sium stearate. The placebo has the identical over encapsula-
tion as the Sertraline tablets.
Administration, dosage and dosage regime on study
medication
After randomisation, patients will be prescribed one capsule
daily of Sertraline hydrochloride (50 mg) or an identical
capsule of placebo. Patients will be reviewed after two
weeks by the research psychiatrist or another mental health
professional to assess mental state and tolerance of the
drug. Dose escalation to a maximum of 100 mg/day will
be allowed if indicated on further assessment by the re-
search psychiatrist at 2 and 4 months.
Data collection
Data will be collected at the six time points: screening
interview, baseline, 2 weeks, 2, 4 and 6 months after
baseline. Patients will be seen at baseline and monthly
during follow-up by the research nurse and by the study
psychiatrist at baseline, 2 weeks and 2, 4 and 6 months
(see Table 1).
Screening
1. Socio-demographic data; primary renal disease; RRT
history; history of depression and other psychological/
psychiatric illness; non-renal comorbidity; baseline
haematological and biochemical parameters including
dialysis adequacy.
2. Questionnaire data – BDI-II [23]; Patient Health
Questionnaire-9 (PHQ-9) [26].
Psychiatric interview
Mini-International Neuropsychiatric Interview (MINI)
version 6.0 [24]; Folstein Mini-Mental Status Exam
[27]; Montgomery-Asberg Depression Rating Scale [25]
(MADRS), Clinical Global Impression – Severity Scale [28].
The research psychiatrist will also assess each patient
for suicide risk, clinically and with reference to item 10 on
the MADRS and question A3G on the MINI. Patients
at significant risk will be excluded from the study, and
referred for further urgent psychiatric assessment.
Trial phase
Baseline Charlson Co-morbidity Index [29]; medications;
electrocardiogram; routine haematological and biochem-
ical parameters, dialysis parameters (see table 1), BDI-II
[23], PHQ-9 [26], MADRS [25], KD-QoL [30] and EQ-5D
[22, 31].
Follow-up Clinical events; changes in medication, routine
biochemical and haematological parameters, dialysis pa-
rameters, PHQ-9 (all monthly) [26], MADRS [25], Clinical
Global Impression – Severity Scale [28], Clinical Global
Impression - Improvement Scale [28], KDQoL [30] and
EQ-5D (2, 4 and 6 months) [22, 31].
Other assessments during follow-up
1. A semi-structured interview enquiring about
patients experiences during the study eg burden of
questionnaires and additional medication, views on
information leaflets.
2. Pre- and post-dialysis blood samples for subsequent
analysis of sertraline levels carried out on one occasion
between 3 and 5 months.
Adverse events (AEs) and serious adverse events (SAEs)
Adverse events will be recorded on the case report forms.
Particular attention will be paid to mood deterioration
which will, if significant or involving increase suicide risk,
trigger review by study psychiatrist. SAEs will be reported
to the CI and sponsors within 24 h. Events which result in
death, threat to life, disability, hospitalisation, or congenital
abnormality or birth defect will constitute SAEs. Hospital-
isation for planned procedures including access surgery will
not be regarded as SAEs.
Emergency unblinding
Blinding can be broken in a medical emergency where
the knowledge of the blinded treatment is necessary such
as deterioration in mood involving suicidal thoughts, or
attempted suicide, cardiac dysrhythmias, GI bleed, sus-
pected serotonin syndrome or neuroleptic malignant syn-
drome, accidental overdose eg by a child in a participants
household, and in the event of a Suspected Unexpected
Serious Adverse Reaction (SUSAR).
Data handling and management
All data collected will be recorded on paper CRFs or the
standardised questionnaires and subsequently entered
by the research staff at each site on to the password-
protected electronic web-based database controlled by
the Data Manager at the Norwich CTU. Regular reports
will be produced including accrual rates and patient pro-
gress though the study, and missing data.
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Table 1 Study assessments
Screening Psychiatric
interview
Entry to
clinical trial
1-2
weeks
1 month 2 months 3 months 4 months 5 months 6 months
Informed Consent X X X
Inclusion/exclusion criteria
fulfilled
X X X
Demographics X
Co-morbid conditions
(self-report)
X
Charlson Co-morbidity Index [29] X X X X X X X
Brief psychiatric history X
BDI-II [23] X X
PHQ-9 [26] X X X X X X X X
P4 Suicidality Screener [33] X X X X
Psychiatric Assessment X X X X X
Montgomery- Asberg
Depression Rating Scale [25]
X X X X
Mini International
Neuropsychiatric Interview [24]
X
List of medications X X X X X X X
Description of dialysis treatment X X X X X X X
Mid-week pre and post dialysis
blood pressure
X X X X X X X X
Dry weight X X X X X X X X
Adherence to dialysis treatment X X X X X X X X
Interdialytic weight gain X X X X X X X X
Urine volume per 24 h X
Dialysis adequacy Kt/V X X X X X X X X
Dialysis time X X X X X X X X
Urea & electrolytesa X X X X X X X X
Full blood countb X X X X X X X X
Liver function testsc X X X X X X X
Electrocardiogram X X X X
IMP review X X X X X X
Drug compliance X X X X X X X
Sertraline Plasma blood test X
Baseline assessment of signs
and symptoms
X
Adverse events X X X X X X X
Kidney Disease QoL
questionnaire [30]
X X X X
Euroqol EQ 5D questionnaire
[22, 31]
X X X X
Clinical Global Impression
Severity Scale [28]
X X X X
Clinical Global Impression
Improvement Scale [28]
X X X
aUrea, Creatinine, Calcium, Sodium, Potassium and Bicarbonate
bHaemoglobin, White blood cell count and platelets
cBilirubin, Albumin, Alanine transaminase (ALT), Aspartate transaminase (AST), Aspartate Aminotransferase, Calcium, Phosphate and C-Reactive Protein
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Data analysis
The primary outcome is to evaluate the feasibility of
conducting a randomised, double blind, placebo pilot trial
in ESRD patients with MDD. This includes the number of
ESRD patients eligible for this clinical trial, safety and drug
exposure of Sertraline in ESRD patients and the patient
experience of participating in this trial. The secondary out-
comes are to estimate the variability in the outcome mea-
sures for the treatment and placebo arms, allowing an
assessment of effect sizes, effects of treatment centre, and
bias due to missing data. The study will also try to evaluate
the gain in the outcome measures in treated patients com-
pared to those in the control group and whether changes
in these measures over time can be attributed to treat-
ment. This is a pilot study and a statistically significant
outcome in this domain is unlikely. Establishing the effect
size though will be of crucial importance in powering
future definitive trials.
Screening data
The primary purpose of the screening phase is to select
patients with a BDI-II of 16 or more who meet the cri-
teria to go forward for psychiatric interview to diagnose
MDD. We will analyse the proportions of patients meet-
ing the inclusion criteria; the proportion refusing to be
screened; and the proportion of patients who screen
positive. The characteristics of these groups will be de-
fined as far as possible. Baseline characteristics for all
patients randomised will be evaluated (means, propor-
tions, counts) for patients in the treatment and placebo
arms. To meet the CONSORT [32] reporting criteria,
the flow of patients through recruitment to this phase of
the study will be recorded, and the numbers of patients
falling into each group evaluated.
Trial process data
The primary analysis will be descriptive, seeking to charac-
terise the acceptability of the study to patients by estimating
the proportions of patients who agree to take part in this
phase and those withdrawing from randomised treatment.
The degree of adherence to the randomised treatment will
also be evaluated to inform future trial design. The analysis
will also characterise the missing data, and seek to deter-
mine the extent to which bias is introduced via missing
data. Lastly, the nature and number of the reported AEs
will be classified. This will help to evaluate the safety profile
of the study drug.
Variability of outcome measures
The aim of this analysis will be to characterise the variabil-
ity of the outcome measures at 6 months, and the related
effect size of treatment versus placebo for each outcome.
Using an “as treated” sample the effect size (cohen’s d) will
be estimated for all the outcome measures. Analysis will
also consider the influence of covariates on the outcome
measures to determine the need for stratification in the
larger RCT to follow, and estimate bias introduced by
missing data and non-completion. Further analysis will
examine the relationship between quality of life and de-
pression scores over time.
Drug exposure
Descriptive data on the levels of Sertraline will allow
inferences on the effect of HD on drug removal.
Discussion
There is a vital need for such a study both in dialysis
and pre dialysis situation since evidence is lacking. We
aim to increase our understanding of the complexities of
conducting research in this population, not just in terms
of outcome but also process. The outputs of this feasibility
study will be used to inform the design and methodology
of a definitive study, adequately powered to evaluate the
efficacy of anti-depressants in ESRD patients on HD and
with a MDD. It is likely this is the forerunner of a larger
study of antidepressants in this population and this will be
an important outcome of this research. We aim to dissem-
inate the results of this study in the renal and psychiatric
peer-reviewed scientific journals as well as conferences
and the wider lay community.
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